文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-FAPI PET/CT与68Ga-DOTATATE PET/CT在神经内分泌肿瘤评估中的对比

68Ga-FAPI PET/CT Versus 68Ga-DOTATATE PET/CT in the Evaluation of a Patient With Neuroendocrine Tumor.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本文报道一名56岁男性多发性肝脏肿块患者,经肝穿刺活检证实为2级高分化神经内分泌肿瘤。68Ga-DOTATATE PET/CT检出胰腺原发灶、肝多发转移及门腔淋巴结转移;对比68Ga-FAPI PET/CT因背景活性低而更清晰显示肝转移灶,原发灶及转移淋巴结也清晰显示。提示FAPI标记放射性核素可能有助于神经内分泌肿瘤的评估与靶向治疗。

要点

  • 68Ga-FAPI PET/CT因低背景活性可更清晰显示神经内分泌肿瘤肝转移灶。
  • 同一患者中68Ga-DOTATATE PET/CT检出胰腺原发灶、肝转移及门腔淋巴结转移。
  • FAPI标记放射性核素可能用于神经内分泌肿瘤评估与靶向治疗。

核心结论

  • FAPI标记放射性核素可能有助于神经内分泌肿瘤的评估和靶向治疗。

研究设计与样本

  • 个案报道:一名56岁男性多发性肝脏肿块患者,肝穿刺活检证实为2级高分化神经内分泌肿瘤,行68Ga-FAPI PET/CT与68Ga-DOTATATE PET/CT对比。

主要发现

  • 68Ga-DOTATATE PET/CT检出胰腺原发肿瘤、肝多发转移及门腔转移淋巴结。
  • 68Ga-FAPI PET/CT因背景活性低而更清晰区分肝转移灶,原发肿瘤及转移淋巴结也清晰显示。

临床怎么用

  • 在神经内分泌肿瘤评估中可考虑FAPI PET/CT以改善肝转移灶的显示。

局限性

  • 仅为单例个案报道,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-FAPI (fibroblast activation protein-specific inhibitor) PET/CT was performed in a 56-year-old man with multiple liver masses, which were confirmed grade 2 well-differentiated neuroendocrine tumors with liver Tru-Cut biopsy. With 68Ga-DOTATE PET/CT, primary tumor in the pancreas, multiple metastases in the liver and metastatic portocaval lymph node were detected. In 68Ga-FAPI PET/CT imaging performed for comparison, it was seen that metastatic lesions in the liver were distinguished much better because of low background activity, and the primary tumor and metastatic lymph node were clearly selected. This case suggested that FAPI-bounded radionuclides may be useful in the evaluation and targeted therapy of neuroendocrine tumors.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kömek H, Gündoğan C, Can C, et al. 68Ga-FAPI PET/CT Versus 68Ga-DOTATATE PET/CT in the Evaluation of a Patient With Neuroendocrine Tumor. Clin Nucl Med. 2021. PMID: 33351508. doi:10.1097/RLU.0000000000003490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。